中文
  • About Us
    Corporate Overview Sr. Management Team Board of Directors
  • Our Science
    Anti-viral Platform RNA Interference Fatty Liver Disease
  • Products & Pipeline
    Overview HCV HBV ASC09 ASC06
  • Partnership
  • Investors
    Financials & Filings
  • News
    2019 2018 2017 2016 2015 2014
  • Careers
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Interpretation of Clinical Research Result of Danoprevir-based Antiviral Regimen in the Treatment of Chronic Hepatitis C Published in Chin J Infect Dis

    2018-12-13

  • Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit

    2018-11-26

  • Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis

    2018-11-20

  • Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer

    2018-11-11

  • Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD

    2018-11-05

 
  • 1
  • 2
  • 3
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备 11050387号